GH
Guardant Health, Inc. Common StockstockNASDAQ
we believe conquering cancer is a big data problem. that's why we built the world's leading comprehensive liquid biopsy. this non-invasive tool for accessing and sequencing tumor dna is used by thousands of oncologists to help tens of thousands of advanced cancer patients. we believe the boom in cancer data acquisition we helped launch will drive important discoveries and new products. we're working on some exciting ones, including in early detection, where the impact on patients can be profound. we've raised more than $500 million from investors including sequoia capital, khosla ventures, orbimed, and softbank.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 158.79 | 2026-11-09 | -8.24% | 0.614 |
| 1M | 158.60 | 2026-10-16 | -8.13% | 1.685 |
| 3M | 161.67 | 2026-08-17 | -9.88% | 1.184 |
| 6M | 94.92 | 2026-05-15 | +53.50% | 1.208 |
| 1Y | 96.48 | 2025-11-17 | +51.02% | 1.338 |
| 2Y | 29.11 | 2024-11-15 | +400.51% | — |
| 5Y | 105.23 | 2021-11-16 | +38.46% | 0.637 |
Guardant Health, Inc. Common Stock (NASDAQ:GH) stock price today is $145.70, and today's volume is 426,304. GH is down 3.955% today. The 30 day average volume is 2.11M. GH market cap is $19.71B with 135.29M shares outstanding.